It will take patience for this to play out, but these articles are setting the bar so low for Belviq that once the real world results start to be documented it will APPEAR as if the FDA grossly underestimated that lorcaserin was capable of.
It will stink for a while because this will take patience. But patience is one of the virtues that sets institutional investing apart from the average retail investor.
I want to say it again. It is the BATHROOM SCALES that will make or break Belviq. 40% of those that take Belviq will lose more than 10% of their weight in a year. The AVERAGE weight loss among all patients that take it will be 8% per year.
BOTH of those figures are being suppressed by articles that do not accurately reflect the actual raw data that 8000 Belviq test subjects experiences. The raw data is the real world experience.
With a bar set at 3% the world will be shocked when weight loss figures that are on AVERAGE nearly 2.5X higher and, in responders, nearly 4X higher start to get reported.